The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s GBS6 or PF-06760805 to prevent invasive Group B Streptococcus (GBS) disease in new-borns and infants through immunisation of women during pregnancy.
Bristol Myers Squibb has completed the previously announced acquisition of Turning Point Therapeutics, for a total consideration of $4.1bn in cash.
Senda Biosciences has raised $123m in Series C financing round to advance the development of its programmable medicines’ platform into clinical testing.
Chinese biotechnology firm Epigenic Therapeutics has secured $20m in Series Angel and Pre-A funding to proceed with next-generation gene editing therapy.
TransCode Therapeutics has entered into a strategic alliance with the University of Texas MD Anderson Cancer Center for advancing its RNA therapies for oncology.
BridGene Biosciences has raised $38.5m in Series B financing round for the development of its next generation chemoproteomic platform, Isobaric Mass Tagged Affinity Characterization (IMTAC), as well as oncology drugs.
The US Food and Drug Administration (FDA) has approved QBiotics Group’s Investigational New Drug (IND) application to commence the Phase II clinical trial (QB46C-H07) of tigilanol tiglate.
Sunnybrook Research Institute (SRI) and Amylyx Pharmaceuticals have joined forces to develop new drug candidates to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
SK Biopharmaceuticals and Brazilian pharmaceutical firm Eurofarma have signed a license agreement to develop and commercialise cenobamate to treat epilepsy in Latin America.
Orion Biotechnology Canada, and Peptilogics have entered a research and development collaboration to leverage artificial intelligence (AI) for drug discovery against an undrugged G Protein-Coupled Receptors (GPCRs) target.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.